Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.
You may also be interested in...
Reckitt CEO Becht’s Exit Has Analysts Expecting Bumps Ahead
Reckitt Benckiser CEO Bart Becht's retirement sparks concern from market analysts, even with the executive currently in charge of the firm’s leading brands, Rakesh Kapoor, named to take the top post.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.